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Poster Session II 103determined by a PCR assay before UD transplant would be associ-
ated with a higher incidence of HC.Methods:We studied prospec-
tively 209 consecutive patients transplanted from 09/05 to 08/07.
Preparative regimens were ablative (n5 118) and reduced intensity
(n5 91); 38 patients (18%) received cyclophosphamide-containing
regimens. GVHD prophylaxis was tacrolimus and mini-methotrex-
ate. Stem cell source was bone marrow (n 5 78), peripheral blood
(n 5 108) and umbilical cord (n 5 23). BK virus quantitative PCR
was performed on urine samples collected at admission for trans-
plant and on days 15, 30, 45 and 60 after transplant. Results: Me-
dian age was 49 years (range, 19–71). Diagnoses were Leukemias
(n 5 161), Multiple Myeloma (n 5 6), Hodgkin’s disease (n 5 7),
Non-Hodgkin’s Lymphomas (n 5 32), and other(n 5 3). Median
follow-up is 246 days (range 7–848). BK PCR was positive in 96 pa-
tients(46%). Number of viral copies ranged from 200 to.200 mil-
lion copies. Twenty-eight patients (13.4%) developed HC, at
a median of 59 days (range 8–225) after HSCT. The 100-day cumu-
lative incidence (using death as a competing risk) of HC in the PCR
positive and negative groups was 13% versus 6% (HR 2.6; 95% CI,
1–6.9; P 5 0.05). The one-year cumulative incidence of HC in the
PCR positive and negative groups was 16% versus 10% (HR 2; 95%
CI, 0.9–4.6; P5 0.09). Incidence of HC (table) was not statistically
significantly increased among recipients of cyclophosphamide-con-
taining regimens or among patients with grade II-IV acute GVHD.
Conclusion: BK viruria pre-HSCT may increase the risk of devel-
oping HC.Incidence of HC
HC Yes (n) %non CTX regimen 20 11
CTX regimen 4 10
GVHD II-IV 8 12
non GVHD 9 10
Ablative regimen 18 15
non-Ablative regimen 6 6
Stem Cell Source
PBSC 13 12
BM 6 7
CB 5 21
BK PCR. 200 million copies 2 25
BK PCR\200 million copies 13 15HC: Hemorrhagic Cystitis; CTX: Cyclophosphamide; PBSC:
Peripheral Blood Stem Cell; BM Bone Marrow; CB: Cord
Blood.278
TREOSULFAN PLUS FLUDARABINE FOR ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) IN PATIENTS WITH ACUTE LEUKEMIA
AND MYELODYSPLASTIC SYNDROME
Nemecek, E.R.1, Ly, B.2, Kovacsovics, T.2, Maziarz, R.T.2,
Baumgart, J.3, Sanders, J.E.4, Deeg, H.J.4. 1Oregon Health & Science
University, Portland, OR; 2Oregon Health & Science University,
Portland, OR; 3Medac GmbH, Hamburg, Germany; 4Fred Hutchinson
Cancer Research Center, Seattle, WA.
Myeloablative regimens followed by allogeneic HCT are effec-
tive in eradicating leukemia, but are associated with a moderately
high risk for regimen-related toxicity (RRT) and transplant-related
mortality (TRM). Nonmyeloablative and reduced intensity regi-
mens, variably defined, have been used with resulting decreased
RRT and NRM, but also higher rates of relapse compared to mye-
loablative regimens. Thus, there is a need to explore alternative reg-
imens with sufficient intensity to mediate anti-leukemic activity
without increasing RRT or TRM. The objective of this ongoing
study was to determine the optimum dose of a new agent, treosul-
fan, in combination with fludarabine prior to allogeneic HCT in pa-
tients with acute myeloid (AML) or lymphoblastic leukemia (ALL)
or myelodysplastic syndrome (MDS). ‘‘Optimal’’ dose was deter-
mined by safety and efficacy, as defined by incidence of severe/fatal
RRT, graft failure and TRM. Thirty-six patients (8 children and 28adults$ 18 years), with a median of 41 (5–58) years, and diagnosed
with AML in first (n 5 19), second remission (n 5 7) or not in re-
mission (n 5 4), ALL in second remission (n 5 2) or MDS (n 5
4) have been treated. Patients were considered to be at high risk
for TRM because of aggressive therapy for a prior malignancy, co-
morbid conditions or previous HCT. Patients received treosulfan at
12 (n5 5) or 14 g/m2/day (n5 31) on days -6 to -4, and fludarabine
(30 mg/kg/day) on days -6 to -2. GVHD prophylaxis was with ta-
crolimus and methotrexate (n5 35) or cyclosporine and methotrex-
ate (n 5 1). Donors were HLA-matched siblings (n 5 19) or
unrelated volunteers (n 5 17); source of stem cells were bone mar-
row (n5 7) or filgrastim-mobilized peripheral blood cells (n5 29).
Neutrophil engraftment occurred at a median of 18 (11–30) days.
Grade II-IV acute graft-versus-host disease (GVHD) was observed
in 9 of 36 patients, and chronic GVHD in 8 of 23 evaluable patients
surviving beyond post-transplant day 80. Dose-limiting RRT was
observed in 1 of 36 patients (mucositis requiring intubation).
With a median follow-up of 118 (20–575) days, estimated one-
year overall and disease-free survival, relapse and TRM are 83%,
78%, 22% and 0%, respectively. Day-100 mortality is 6%. Treosul-
fan/fludarabine is a well-tolerated regimen with promising disease
control and low rates of RRT and TRM in patients with acute leu-
kemia and MDS. Further studies are warranted to evaluate the effi-
cacy of this regimen.279
MODIFICATION OF T CELL RESPONSES BY STEM CELL MOBILIZATION
REQUIRES DIRECT SIGNALLING OF THE T CELL BY G-CSF AND IL-10
MacDonald, K.P.A., Bofinger, H.M., Kuns, R.D., Morris, E.S.,
Don, A.L., Banovic, T., Hill, G.R. Queensland Institute of Medical Re-
search, Brisbane, Queensland, Australia.
G-CSF is increasingly described as a therapy for a diverse range
of diseases and although the mechanisms involved remain unclear,
IL-10 is thought to play a key role as a regulatory effector molecule.
Since G-CSF is used as a stem cell mobilizing agent, we generated
mixed radiation chimeras as stem cell donors in which haemato-
poietic or non-haematopoietic compartments were wild-type
(WT), IL-10-/-, G-CSFR-/- or combinations thereof. T cells from
donors mobilized with G-CSF had impaired ability to induce
GVHD only when the haematopoietic compartment was G-
CSFR competent, whereas G-CSFR signalling within the non-hae-
matopoietic compartment was irrelevant. Furthermore, we demon-
strate that the attenuation of T cell function requires direct
signalling of the T cell by G-CSF. Using G-CSF mobilized IL-
10-/- radiation chimeras as SCT donors, when the non-haemato-
poietic compartment was WT, T cells had impaired ability to
induce GVHD regardless of their ability to secrete IL-10. In con-
trast, T cells from chimeric donors in which the non-haemato-
poietic compartment was IL-10-/- universally induced severe
GVHD. Thus, the induction of regulatory T cell function by
stem cell mobilization occurs as a consequence of direct T cell sig-
nalling by G-CSF in conjunction with IL-10 derived from non-hae-
mopoietic cells. The IL-10 receptor is highly expressed by T cells,
particularly CD41CD251 regulatory T cells and their depletion
from G-CSF treated, but not control grafts, significantly increases
graft-versus-host disease (survival 25% v 75% Treg depleted vs
non-depleted donors P 5 0.002). These studies provide the expla-
nation for the profound effects of G-CSF on T cell function and
demonstrate that IL-10 is required to license regulatory function
but is not required as an effector molecule.280
SEROLOGICAL EVIDENCE OF HEPATITIS C IS ASSOCIATEDWITHWORSE
NON-RELAPSE MORTALITY AND OVERALL SURVIVAL AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Ramos, C.A., Saliba, R.M., Khorshid, O., de Padua, L., Giralt, S.,
Andersson, B.S., Ueno, N.T., Shpall, E.J., Hosing, C., Qureshi, S.R.,
Champlin, R.E., de Lima, M. The University of Texas MD Anderson
Cancer Center, Houston, TX.
Active chronic hepatitis C (HC) is associated with perturbed im-
munity, but the influence of HC virus infection on the outcomes of
104 Poster Session IIpatients undergoing allogeneic hematopoietic stem cell transplanta-
tion (alloSCT) is unclear. We performed a retrospective matched-
control study of the outcomes of 31 patients with serological evi-
dence of HC at the time they underwent alloSCT for a variety of
hematological malignancies between 1998 and 2007 at the UTM-
DACC. For comparison, we identified 31 control patients with neg-
ative serology for HC, matched on age group, diagnosis, disease risk
(poor vs. good), intensity of conditioning regimen (reduced vs. mye-
loablative) and donor type (referred to as matched controls). To con-
firm the validity of the matching procedure we extended the
comparison to the 1800 seronegative patients (all controls) trans-
planted for the same diseases during the same period of time. Mul-
tivariate analysis took into account all variables used in our
matching procedure.
The median age of the HC patients was 49 (range 26–72); 15 had
AML/MDS, 6 CML/MPD, 6 non-Hodgkin lymphoma, 2 mye-
loma, 1 ALL and 1 Hodgkin lymphoma; 61% of had poor risk dis-
ease, 68% had related donors, and 68% received reduced intensity
conditioning. These characteristics were identical to those of the
matched control group. There were also no significant differences
in baseline liver function: immediately prior to starting condition-
ing, only 7 patients in the HC group and 5 patients in the matched
control group had an alanine transaminase (ALT) level greater than
the upper limit of normal (ULN), but all less than 3ULN (ranges
69–185 and 69–178 IU/L); only one patient in the HC group (versus
none in the matched control) had a total bilirubin level above the
ULN (1.2ULN).
Median follow-up was 34 (range 3–53), 27 (4–74) and 29 months
(1–108), respectively for HC, matched and all controls. Overall sur-
vival post-alloSCT was significantly inferior in the HC group, with
a median OS of 3 versus 18 and 20 months in the control groups.
The cumulative rate of disease progression and acute or chronic
GVHD was comparable, but NRM was significantly increased in
the HC group. Results were similar regardless of the control group
used, validating our matching algorithm. In summary, serological
evidence of HC virus infection at the time of alloSCT, even with
normal or minimally abnormal liver function tests, is associated
with worse survival after alloSCT, due to an increased rate of
non-relapse deaths.Patients with hepatitis C have worse overall survival and non-relapse
mortality than controls after SCT
Matched analysis Multivariate analysisOutcome
mHC (N 5 31) vs.
atched controls
(N 5 31), % HR (95% CI) PHC (N 5 31) vs.
all controls
(N 5 1800), % HR (95% CI) POS:3 mo 58 vs. 87 3.6 (1.2–11.0) 0.03 58 vs. 87 3.9 (2.2–6.8) \0.001
1 yr 29 vs. 56 2.4 (1.2–4.9) 0.01 29 vs. 56 3.1 (1.9–5.6) \0.001NRM:3 mo 29 vs. 13 2.5 (0.8–8.1) 0.1 29 vs. 10 3.6 (1.8–7.1) \0.001
1 yr 43 vs. 24 2.9 (1.1–7.7) 0.03 43 vs. 23 3.3 (1.9–5.6) \0.01HC: hepatitis C, OS: overall survival, NRM: non-relapse mortality,
HR: hazard ratio, CI: confidence interval.281
SERIAL VORICONAZOLE THERAPEUTIC DRUG MONITORING IN RECIPI-
ENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Trifilio, S.M.1, Yarnold, P.R.1, Pennick, G.2, Pi, J.C.1, Golf, M.1,
Fishman,M.1, Masino, K.1, Mehta, J.1. 1Northwestern University, Chi-
cago; 2University of Texas at San Antonio, San Antonio.
Voriconazole is effective for prophylaxis and therapy of invasive
fungal infections (IFI). It is metabolized by the CYP450 system
2C19, 2C9 and 3A4 isosenzymes. We have reported that significant
interpatient variability exists in plasma voriconazole concentrations
after allogeneic HSCT and that about 15% of patients have no de-
tectable voriconazole in the plasma despite adequate dose (Trifilio
et al. Cancer 2007;109:1532–1535). Low plasma levels have alsobeen associated with decreased survival in patients with aspergillosis
and increased breaktrough Candida glabrata infections (Trifilio et
al. Bone Marrow Transplant 2007;40:451–456). Treatment or pro-
phylaxis for IFIs after HSCT is prolonged, and changing conditions
are likely to alter voriconazole pharmacokinetics which may predis-
pose to treatment failure. We studied the relationship between the
first and second voriconazole levels in 29 allogeneic HSCT recipi-
ents whose first plasma voriconazole level was adequate (.2 mg/
mL). The first level was drawn 6 days after starting voriconazole
(usually day 16 post-HSCT), and the second level was drawn at
a variable time after the first (median 9 days; range 1–252 days).
The majority of patients received the drug at the dose of 200 mg
twice a day orally. The two levels were strongly correlated to
each-other (r 5 0.72; p\ 0.0001), but not to the interval between
the two (p\ 0.6) or weight (p\ 0.49). 10 patients had a level\2
mg/mL on the second measurement. Optimal discriminant analysis
revealed that all 11 patients with an initial voriconazole level #4.6
mg/mL had a second level that was\2 mg/mL (p\ 0.02). Neither
the interval between the two levels (p \ 0.15) or weight (p \
0.75) predicted whether a patient’s second voriconazole level was
\2 mg/mL. However, when the analysis was expanded to a total
of 43 patients in whom the first level was $1 mg/mL, 10 of whom
had a second level of\1 mg/mL, no factor could be found that could
reliably predict for a second level of\1 mg/mL. These data suggest
that serial plasma voriconazole levels can change in an unpredict-
able fashion over time after HSCT - sometimes decreasing to levels
that may place the patient at risk for breakthrough IFIs. Patients
who require prolonged voriconazole administration may benefit
from ongoing therapeutic drug monitoring and dose adjustment.282
EFFICIENT INDUCTION AND ISOLATION OF A PRIMARY CMV-SPECIFIC
CD81 T CELL RESPONSE FROM CMV SERONEGATIVE DONORS FOR
THE TREATMENT OF SERIOUS CMV-RELATED COMPLICATIONS IN
CMV SEROPOSITIVE PATIENTS TRANSPLANTEDWITH A CMV SERONEG-
ATIVE DONOR
Jedema, I., van de Meent, M., van der Heiden, P.L.J., Marijt, E.W.A.,
Meij, P., Willemze, R., Falkenburg, J.H.F. Leiden University Medical
Center, Leiden, Netherlands.
Cytomegalovirus (CMV) disease is a significant cause of morbid-
ity and mortality after allogeneic stem cell transplantation
(allo-SCT). Especially in CMV seropositive (CMV1) patients
transplanted with a CMV- donor, a high incidence of CMV related
mortality is seen. We recently demonstrated in a phase I/II clinical
study the feasibility of selecting CMV-specific CD81 memory T
cells from CMV1 donors using the interferon-gamma (IFNg) cap-
ture assay and CliniMACS isolation after peptide stimulation of the
CMV-specific donor T cells. We have illustrated the in-vivo poten-
tial of these T cells after adoptive transfer in 5 patients with persis-
tent CMV reactivation despite seropositivity of the donor, resulting
in clearance of the CMV load. However, no suitable method was
available for the induction of primary immune responses against
CMV for the treatment of persistent CMV reactivation in the
high risk group of patients transplanted with a CMV- donor. In
the current study we investigated the possibility to induce and iso-
late CMV-specific T cells from CMV- healthy donors by in-vitro
priming and selection. We used as responder cells CD45RO-
PBMC from HLA-A1, A2, A3, B7, or B8 positive CMV- donors
(n5 13). By CD45RO depletion we removed the majority of regu-
latory T cells capable of inhibiting the initiation of the response.
Naı¨ve donor T cells were cocultured in the presence of IL-7 and
IL-15 with mature monocyte-derived dendritic cells loaded with
a cocktail containing 1mg of each relevant CMV pp65, pp50, or
IE1 derived 9-mer peptide. At day 10, the responses were specifi-
cally restimulated with peptide loaded autologous PBMC. At day
20 CMV-specific CD81 T cells were detected by specific tetramer
or pentamer staining, and isolated by flowcytometric cell sorting or
magnetic bead isolation, or further enriched by another restimula-
tion, followed by isolation of CD137 or IFNg expressing T cells
at day 21. In 13/13 CMV- donors CMV specific T cells could be de-
tected at day 20 of the immune response in frequencies ranging
from 0.01–0.4%. Functional CMV-specific T cells against all 3 ma-
jor immunogenic CMV proteins pp65, pp50, and IE1 were isolated
